Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor

KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio

Stipple Bio raises $100M Series A to advance next-gen cancer therapies

The new capital is expected to fund the company through 2029

Lupin wins USFDA nod for generic Dapagliflozin tablets

Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size

Aurobindo Pharma wins USFDA approval for generic Xigduo XR

Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually

Thailand and GHIT Fund join forces to tackle infectious diseases

The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand

Alembic Pharma wins USFDA nod for generic Dapagliflozin, secures 180-day exclusivity

Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.

Apollo report warns India’s silent health risks are striking earlier among young adults

Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals